🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523562-24-00
Authorised Phase I

A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a single dose of REGN22044 in Healthy Adults

2025-523562-24-00 · tracked via the Priya Life Science EU tracker
Sponsor
Regeneron Pharmaceuticals Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Not possible to specify
Decision date
11/05/2026
Enrollment target
64
Sites
Belgium

Condition studied

Heathy volunteer trial

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523562-24-00 on CTIS ↗ ← All trials in the EU